As Associate Director for Clinical Research since 2018, Howard S. Hochster, MD is responsible for the oversight of clinical research development and clinical trial activity at the Cancer Center, planning and evaluation of developing and established clinically focused Research Programs, and representation of clinical science in Center strategic planning. Hochster received his MD from the Yale School of Medicine in 1980 and completed his residency in Internal Medicine at Bellevue Hospital and NYU School of Medicine. He continued at NYU for his hematology and oncology fellowship (under Franco Muggia and Robert Silber). He also spent a fellowship year studying new drug development, phase I trials and pharmacology at the Institute Jules Bordet in Brussels with Martine Piccart and Jean Klastersky. He returned to NYU as faculty with an ACS Career Development Award and focused on new drug development of anthracycline analogs and topoisomerase-1 inhibitors. He developed fludarabine for lymphoma with ECOG and chaired the pivotal E1496 trial of maintenance rituximab. He was successfully awarded two R01 grants. He became involved with clinical trials management at NYU, heading the Clinical Trials Office, and chairing the Protocol Review Committee. Focusing more on GI oncology, he became an internationally recognized expert for development of oxaliplatin, irinotecan, bevacizumab and cetuximab alone and in combination. In 2010, he became Associate Director for Clinical Sciences and head of GI Oncology at the Yale Cancer Center. Hochster joined CINJ in January 2018 as Associate Director for Clinical Research and Director of GI Oncology. He is co-editor of the journal Oncology, associate editor for the JNCI, and on the editorial board of Journal of Clinical Oncology. In his recognized role as an expert in clinical research, he currently serves as a member of Joint RU-RWJBH Steering Committees for Clinical Research (in part overseeing the CTSA) and for Informatics. He advises the CTSA (NJACTS) on their clinical trials office function, structure, and Scientific Review process. He participates with the RU-RWJBH research structure on the Combined Research Oversight Committee and the IT Steering Committee.